Dr. Uzzo on Biomarker Development for RCC | OncLive

Dr. Uzzo on Biomarker Development for RCC

November 10, 2017

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses biomarker development for patients with renal cell carcinoma (RCC).

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses biomarker development for patients with renal cell carcinoma (RCC).

There are currently no biomarkers for patients with RCC, states Uzzo. Researchers are investigating immunohistochemical stains as a potential biomarker, but further research is needed.

According to Uzzo, the most effective biomarker will be easily collected and will have a high sensitivity and specificity.


x